Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation.

导出 LinkOut

翻译打印收藏纠错

第一作者： Daniele,Raggi

第一单位： Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

作者： Daniele,Raggi ^[1] ; Luigi,Mariani ^[2] ; Patrizia,Giannatempo ^[1] ; Salvatore,Lo Vullo ^[2] ; Daniele,Giardiello ^[2] ; Nicola,Nicolai ^[3] ; Luigi,Piva ^[3] ; Davide,Biasoni ^[3] ; Mario,Catanzaro ^[3] ; Tullio,Torelli ^[3] ; Silvia,Stagni ^[3] ; Massimo,Maffezzini ^[3] ; Giuseppina,Calareso ^[4] ; Michele,Magni ^[1] ; Massimo,Di Nicola ^[1] ; Elena,Verzoni ^[1] ; Paolo,Grassi ^[1] ; Giuseppe,Procopio ^[1] ; Filippo,De Braud ^[1] ; Giorgio,Pizzocaro ^[3] ; Roberto,Salvioni ^[3] ; Andrea,Necchi ^[5]

作者单位： Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. ^[1] Clinical Epidemiology and Trials Organization Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. ^[2] Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. ^[3] Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. ^[4] Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: andrea.necchi@istitutotumori.mi.it. ^[5]

关键词 Germ cell tumor Intermediate Risk Prognosis Survival Testicular cancer